Efficacy of potassium polycitrate on renal stone and microlithiasis predisposed by metabolic disorders

Abstract

Background: According to high prevalence of renal stone in children, we evaluated the efficacy of treatment with potassium citrate and its correlation with metabolic disorders in children less than two years of age with renal stone and microlithiasis.

Methods: In this cross-sectional study, 100 patients (less than 2 years old) with renal stone or microlithiasis were evaluated for metabolic disorders. They were treated with potassium citrate and followed-up by ultrasonography every 3 months. Then response to treatment was evaluated according to the presence of metabolic disorders (A p-value<0.05 was significant).

Results: According to this study, hyperuricosuria and hypercalciuria were the two major metabolic disorders (40-33%). Seventy three patients had complete response, and also there was not a significant difference (p<0.05) in the efficacy of treatment due to types of metabolic disorders. There was significant difference between relative response to treatment in children who had metabolic disorders and patient without any metabolic disorders.

Conclusion: Based on our results the use of potassium citrate in all children less than 2 years with renal stone or microlithiasis especially those with metabolic disorders, are recommended.

Keywords: Renal stone, Potassium polycitrate, Hypercalciuria, Hyperuricosuria, Metabolic disorders, Children less than 2 Years.

Citation:
Hadi S, Saeedizand N, Poornasroallah M, Bijani A. Efficacy of potassium polycitrate on renal stone and microlithiasis predisposed by metabolic disorders. Caspian J Intern Med 2017; 8(4): 296-300.

Nephrolithiasis is common yet an important problem in children. Its prevalence has increased because of change of diet, lifestyle and consumption of some drugs. The prevalence of nephrolithiasis is 1.7–4.1% in females and 4-9% in males (1, 2). The prevalence of renal stone has increased five times in recent years (3). About 40% of children with renal stone have a positive familial history (4). Renal stone disease is less common in children than adults, and it is more commonly associated with metabolic disorders or anatomical malformation of the urinary tract (5). Although the underlying cause cannot always be identified, infections, diet and environmental factors may influence stone formation in all age groups (6). One of the most important aspects in pediatric urolithiasis is the different clinical manifestation. Some infants and younger children may be asymptomatic and older children may present with abdominal pain and nonspecific symptoms (7). The purpose of treatment in children is to diminish the risk of stone formation, preserving the kidney function and decreasing the rate of recurrence. Although sometimes surgical intervention may be needed (8). Medical treatments of nephrolithiasis are as follows: increase fluid intake, restrict sodium, and use analgesics in cases of which pain persisted (9).
Potassium citrate is one of the drugs used in nephrolithiasis and its efficacy is being investigated. Citrate prevents the formation of calcium deposits. Also, it inhibits calcium oxalate crystal that can be a nucleus for renal calculi. Plus, citrate increases the urine pH and prevents the formation of uric acid and cysteine stones (10). In the study by Zamonarski et al., potassium citrate was completely safe in therapeutic dosage, in addition, they found that the physiological citrate level in urine is more than other inhibitor agents and therapeutic dosage may cause only a mild metabolic alkalosis. Improvement was seen in 70-75% of cases in one year (11). In a cohort study by Tekin et al., it was observed that 1 mEq/kg potassium citrate per day decreased stone recurrence and normalized urinary citrate level in children 1-15 years old (12).

Most studies are about kidney stone prevention in children and adults (13, 14). There are limited investigations about the efficacy of potassium citrate in children with metabolic disorders (15, 16). Regarding the complications of pediatric nephrolithiasis, a non-invasive, inexpensive and accessible treatment like potassium citrate can be useful. In this study, we investigated the effect of potassium polycitrate on and the correlation between metabolic abnormalities renal stone in children less than 2 years old.

Methods

In this cross-sectional study, all patients less than two years old who were referred to nephrology clinic and department and had renal stone or microlithiasis (deposits < 3 mm) in ultrasonography were enrolled. Twenty five patients with urinary tract infection, cystic fibrosis and anatomical abnormalities were excluded. Complete metabolic evaluation plus blood urine nitrogen (BUN), creatinine, sodium, potassium, vein blood gas, calcium, phosphate, alkaline phosphatase, uric acid were done. The random urine sample was checked for calcium, creatinine, uric acid and citrate level.

Hypercalciuria was defined if early morning calcium/creatinine ratio was >0.8, >0.6 and <0.21 in neonates, 6-12 months and 1-2 years, respectively. Uric acid to creatinine ratio more than 1 was defined hyperuricosuria. Additionally, the oxalate to creatinine ratio <147 and <72 in children less than 6 months while 7-24 months were normal, respectively. Hypocitraturia was defined as citrate to creatinine ratio of less than 0.51. The existence of urine cysteine was evaluated qualitatively by cyanide-nitroprusside test. Medical treatment with potassium poly citrate (citric acid 22% and potassium citrate 6.88%) 1 ml/kg was done. The dosage of drug was decreased or increased according to urine pH (between 6-7). Moreover, in children with hypercalciuria, hydrochlorothiazide (1-2 mg/kg) was prescribed to achieve the normal level of urine calcium. Patients were followed-up by ultrasonography every 3-4 months. (patients ultrasonography was performed by the same radiologist who evaluated the patients for the first time). The information was collected based on the number or size of stone or microlithiasis, age, sex, and the kind of metabolic disorder. Response to medication was assessed as relative or complete response to potassium polycitrate treatment. Relative response included the reduction of number and size of stone to 30% and complete response was defined if all stones disappeared, too. The information was analyzed by Kaplan-Meier method of which the significant level was set at 0.05.

Results

In this study, the data from the 100 patients who were less than 2 years old with renal stone or microlithiasis confirmed by ultrasonography were analyzed. Fifty-eight percent were boys and forty-two percent were girls. The mean age of patient was 6.9±4.9 months. The mean size of stones was 2.5±0.8 mm and the mean number of stone was 3.4±2.6. Fifty-two percent of the patients had one side of the body and forty-eight percent had both sides of urolithiasis.

In 200 units of kidney, fifty-two (26%) units did not have any stone or microlithiasis and 148 (74%) units had nephrolithiasis. Among the 100 subjects who were studied, the most common metabolic abnormality were hyperuricosuria (40%) followed by hypercalciuria (33%), hyperoxaluria (28%), hypocitraturia (18%) and cystinuria (2%). Twenty-two percent of patients did not have any known metabolic abnormalities and 36% had more than one metabolic disorder. All the patients were treated with potassium poly citrate and were followed-up by ultrasonography, seventy-three percent had complete response and the relative response was seen in 14% of patients. Thirteen percent of children did not have any response to medication. Table 1 shows the frequency of metabolic disorders and the rate of response to potassium polycitrate in both sexes.
Table 1: Frequency of renal stone or microlithiasis due to metabolic disorders and response to potassium polycitrate in children less than 2 years

| Metabolic disorder        | Negative response | Complete response | Relative response | Frequency and relative frequency |
|---------------------------|-------------------|-------------------|------------------|---------------------------------|
| Hyperuricosuria (total)   | 3 (7.5)           | 30 (75)           | 7 (17.5)         | 40 (40)                         |
| Female                    | 1 (5.3)           | 16 (84.2)         | 2 (10.5)         | 19 (45.2)                       |
| Male                      | 2 (9.5)           | 14 (66.7)         | 5 (23.8)         | 21 (36.2)                       |
| Hypercalciuria (total)    | 1 (3)             | 26 (78.7)         | 6 (18.2)         | 33 (33)                         |
| Female                    | 1 (5)             | 1 (5)             | 18 (90)          | 20 (47.6)                       |
| Male                      | 0                 | 8 (61.5)          | 5 (38.5)         | 13 (22)                         |
| Hyperoxaluria (total)     | -                 | 25 (89)           | 3 (11)           | 28 (28)                         |
| Female                    | 0                 | 15 (96)           | 1 (4)            | 16 (38)                         |
| Male                      | 0                 | 10 (83.3)         | 2 (16.7)         | 12 (20)                         |
| Hypocitraturia (total)    | 2 (11)            | 11 (61.3)         | 5 (27.5)         | 18 (18)                         |
| Female                    | 1 (25)            | 2 (50)            | 1 (25)           | 4 (9.5)                         |
| Male                      | 1 (7.1)           | 9 (64.4)          | 4 (28.5)         | 14 (24)                         |
| Cystinuria                | 1 (50)            | 1 (50)            | 0                | 2 (2)                           |
| Female                    | 0                 | 1 (100)           | 0                | 1 (2.3)                         |
| Male                      | 1 (100)           | 0                 | 0                | 1 (1.7)                         |
| Without known metabolic disorders | 7 (31.8)       | 12 (54.5)         | 3 (13.7)         | 22 (22)                         |
|                           | 2 (40)            | 3 (60)            | 0                | 5 (12)                          |
|                           | 5 (29.4)          | 9 (52.9)          | 3 (17.7)         | 17 (29.3)                       |

In 22% of patients, any known metabolic abnormality was not found and among them, the rate of response to treatment was 73%. Twenty-seven percent had no response to medication, 36% of patients had more than one metabolic disorder. In this study, we investigated the possible differences in metabolic abnormalities between boys and girls. However, we did not find significant differences in prevalence of all the investigated metabolic parameters (table 1).

According to COX regression results for relative or complete response to treatment, factors such as of age, sex, kind of metabolic disorder, size of stones, renal stone on one side and multiple stones on both sides did not have significant difference (table 2). The only significant difference was more relative response to treatment in children who had metabolic disorders in comparison with patient who did not have any known metabolic abnormalities (P=0.045) (figure 1).

Table 2. Multivariant COX regression results for relative and complete response to potassium polycitrate in children less than 2 years old with renal stone or microlithiasis

| Parameter          | Relative response HLR (CI 95%) | P-value | Complete response HLR (CI 95%) | P-value |
|--------------------|--------------------------------|---------|--------------------------------|---------|
| Sex                | 0.88 (0.54-1.44)               | 0.632   | 0.95 (0.56-1.63)               | 0.876   |
| Stone Size         | 0.87 (0.68-1.12)               | 0.293   | 0.77 (0.57-1.03)               | 0.84    |
| Hypercalciuria     | 1.28 (0.81-2.03)               | 0.278   | 1.44 (0.87-2.40)               | 0.152   |
| Hyperoxaluria      | 1.26 (0.78-2.03)               | 0.340   | 1.29 (0.78-2.14)               | 0.316   |
| Hypocitraturia     | 1.12 (0.638-1.99)              | 0.681   | 0.88 (0.46-1.69)               | 0.709   |
| Hyperuricosuria    | 1.19 (0.77-1.82)               | 0.418   | 1.07 (0.67-1.71)               | 0.763   |
| Multistone         | 0.77 (0.41-1.47)               | 0.442   | 0.56 (0.28-1.12)               | 0.104   |
| Stone in Both sides | 1.19 (0.685-2.08)             | 0.531   | 0.93 (0.5-1.73)                | 0.82    |
Discussion

According to this study, the most common metabolic abnormality was hyperuricosuria (40%) and then hypercalciuria (33%). Furthermore, about 73% of patients had complete response to polycitrate-K and 13% of patients had no response to drug. In about 20% of children, no metabolic disorders were detected. In one study done on 151 infants (under 1 year old) in south of Iran, the mean age of patients was 5.46 months and the most metabolic abnormality was hypercalciuria (79%) (17). In Elmaci et al.’s study on 143, 2-6 year-old children, 83.3% of patients had metabolic abnormalities. Hyperuricosuria (24.5%) was the most common abnormality followed by hypercalciuria (21%) (18). Naseri et al. reported 42.7% of metabolic abnormalities in 142 children, 17.6% of them with hypercalciuria and 16.1% of patients had hyperuricosuria. Further, 11.2% of children had multiple metabolic abnormalities (19). Camberari et al. divided all children into two groups, there under and above 10 years old in which metabolic abnormalities were seen in 75% of children under 10 years old and in 60% of children more than 10 years old. Hypercalciuria was the most inherited metabolic disorder in children more than 10 years old and hypocitraturia was the major inherited metabolic disorder in children under 10 years old (20). According to these studies, hypercalciuria and hyperuricosuria were the most common metabolic abnormalities in children with renal stone. The difference of these causes may be due to culture, race, nutrition and geography. Likewise, the difference of age groups in these studies may be another cause of different metabolic abnormalities. Nonetheless, hypercalciuria and hyperuricosuria were the most common abnormalities and further studies may be needed to evaluate them. The male to female ratio of this study was 1.4. Tekin et al. reported 1.67 and in Sarica’s study, the ratio was 1.36 (12, 21).

The risk of renal stone was higher in males in all studies and more attention and follow-up may be needed in male children. About half of the children had bilateral kidney involvement. In Tekin’s study; about 30% of patients had bilateral involvement (12). Renal stones in both kidneys may be due to metabolic disorders. In this study, 87% of patients had response to polycitrate-K in which 73% of them had complete response and 13% did not have any response. Patients with hyperoxaluria had the best response. In addition, children with metabolic abnormality had better response to drug than the patients without any detected abnormality (91% vs 72%).

In Sorkhi et al.’s study done on children with mean age of 36.7±37.4 month, 78.7% of patients had complete response to polycitrate-K (22). Tekin et al. reported decrease of renal stone recurrence in children with hypocitraturia who were treated with polycitrate-K (12). In another study by Naseri et al., complete response was seen in 50% of patients with renal stone and hypercalciuria treated with citrate-K and hydrochlorothiazide (23). Volkan showed significant decrease of renal stone recurrence in 17 children with cystinuria who were treated with high volume fluid intake, restricted of salt and citrate-K (24). Majority of studies were done to prevent renal stone and this study showed the effective treatment of renal stone with polycitrate-K in children less than 2 years of age.

In conclusion according to this study, hyperuricosuria and hypercalciuria seem to be the most important metabolic factors of nephrolithiasis in children less than 2 years old. Moreover, according to high response to polycitrate-K in this study, we recommend the use of this drug in all children less than 2 years with renal stone or microlitiasis.

Acknowledgments

We are grateful to the Clinical Research Development Committee of Amirkola Children's Hospital, the Research Council and Non-Communicable Pediatric Diseases Research Center, Health Research Center of Babol University of Medical Sciences for their support and cooperation in this study.
**Funding:** This study was supported by a research grant and Medical thesis of Dr Nazanin Saeedizand from the Non-Communicable Pediatric Diseases Research Center of Babol University of Medical Sciences

**Conflict of interest:** There was no conflict of interest.

**References**

1. Guan N, Fan Q, Ding J, et al. Melamine-contaminated powered formula and urolithiasis in young children. N Engl J Med 2009; 360: 1067-74.

2. Kobayashi T, Okada A, Fujii Y, et al. The mechanism of renal stone formation and renal failure induced by administration of melamine and cyanuric acid. Urol Res 2010; 38: 117-25.

3. VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 2007; 177: 2300-5.

4. Vant Hoff WG. Aetiological factors in paediatric urolithiasis. Nephron Clin Pract 2004; 98: 45-8.

5. Bergsland KJ, Coe FL, White MD, et al. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int 2012; 81: 1140-8.

6. Baştuğ F, Gündüz Z, Tülpar S, Poyrazoğlu H, Düşünsel R. Urolithiasis in infants: evaluation of risk factors. World J Urol 2013; 31: 1117-22.

7. Cameron MA, Sakhaee K, More OW. Nephrolithiasis in children. Pediatr Nephrol 2005; 20: 1587-92.

8. Fahlenkamp D, Noack B, Lebentrau S, Belz H. Urolithiasis in children rational diagnosis, harpy, and metaphylaxis. Urologie A 2008; 47: 545-50, 552-5.

9. Saftar B, Degutis LC, Landry K, et al. Intravenous morphine plus Ketorolac is superior to either drug alone for treatment of acute renal colic. Ann Emerg Med 2006; 48: 173-81.

10. Soygur T, Akbay A, kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol 2002; 16: 149-52.

11. Zmonarski SC, Klinger M, Puziewiez-Zmonarska A, et al. Therapeutic use of potassium citrate. Przegl Lek 2001; 58: 82-6.

12. Tekin A, Tekgul S, Atsu N, Bakkaloglu M, Kendi S. Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. J Urol 2002; 168: 2572.

13. Mokhless IA, Sakr MA, Abdeldeaim HM, Hashad MM. Radiolucent renal stones in children: combined use of shock wave lithotripsy and dissolution therapy. Urology 2009; 73: 772-5.

14. Spivacow FR, Negri AL, Polonsky A, Del Valle EE. Long-term treatment of renal lithiasis with potassium citrate. Urology 2010; 76: 1346-9.

15. Sarica K, Erthurhan S, Yurtseven C, Yagci F. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. J Endourol 2006; 20: 875-9.

16. Stitchantrakul W, Kochakarn W, Ruangraksa C, Domrongkitchaiporn S. Urinary risk factors for recurrent calcium stone formation in Thai stone formers. J Med Assoc Thai 2007; 90: 688-98.

17. Alemzadeh-Ansari MH, Valavi E, Ahmadzadeh A. Predisposing factors for infantile urinary calculus in south west of Iran. Iranian J Kidney Dis 2014; 8: 53-7.

18. Elmaci AM, Ece A, Akin F. Clinical characteristics and metabolic abnormalities in preschool- age children with urolithiasis in southeast Anatolia. J Pediad Urol 2014; 10: 495-9.

19. Naseri M. Urolithiasis in Asian children: evaluation of metabolic factors. J Pediad Biochem 2013; 3: 225-38.

20. Cambareri GM, Kovacevic L, Bayne AP, et al. National multi-institutional cooperative on urolithiasis in children: Age is a significant predictor of urine abnormalities. J Pediad Urol 2015; 11: 218-23.

21. Sarica K. Pediatric urolithiasis: etiology, specific pathogenesis and medical treatment. Urology 2006; 34: 96-101.

22. Sorkhi H, Hedaiai F, Bijani A. Efficacy of potassium citrate solution in children with renal stone. J Babol Univ Med Sci 2011; 13: 73-9. [in Persian]

23. Naseri M, Sadeghi R. Role of high-dose hydrochlorothiazide in idiopathic hypercalciuric urolithiasis of childhood. Iran J Kidney Dis 2011; 5: 162-8.

24. Izol V, Aridogan IA, Karsli O, Deger M, Satar N. The effect of prophylactic treatment with Shohl’s solution in children with cystinuria. J Pediad Urol 2013; 9: 1218-22